A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.

Journal Article (Journal Article)

INTRODUCTION: Over the past decade, the potential for drug-associated progressive multifocal leukoencephalopathy (PML) has become an increasingly important consideration in certain drug development programmes, particularly those of immunomodulatory biologics. Whether the risk of PML with an investigational agent is proven (e.g. extrapolated from relevant experience, such as a class effect) or merely theoretical, the serious consequences of acquiring PML require careful risk minimisation and assessment. No single standard for such risk minimisation exists. Vedolizumab is a recently developed monoclonal antibody to α4β7 integrin. Its clinical development necessitated a dedicated PML risk minimisation assessment as part of a global preapproval regulatory requirement. OBJECTIVE: The aim of this study was to describe the multiple risk minimisation elements that were incorporated in vedolizumab clinical trials in inflammatory bowel disease patients as part of the risk assessment and minimisation of PML programme for vedolizumab. METHODS: A case evaluation algorithm was developed for sequential screening and diagnostic evaluation of subjects who met criteria that indicated a clinical suspicion of PML. An Independent Adjudication Committee provided an independent, unbiased opinion regarding the likelihood of PML. RESULTS: Although no cases were detected, all suspected PML events were thoroughly reviewed and successfully adjudicated, making it unlikely that cases were missed. CONCLUSION: We suggest that this programme could serve as a model for pragmatic screening for PML during the clinical development of new drugs.

Full Text

Duke Authors

Cited Authors

  • Parikh, A; Stephens, K; Major, E; Fox, I; Milch, C; Sankoh, S; Lev, MH; Provenzale, JM; Shick, J; Patti, M; McAuliffe, M; Berger, JR; Clifford, DB

Published Date

  • August 2018

Published In

Volume / Issue

  • 41 / 8

Start / End Page

  • 807 - 816

PubMed ID

  • 29737503

Pubmed Central ID

  • 29737503

Electronic International Standard Serial Number (EISSN)

  • 1179-1942

Digital Object Identifier (DOI)

  • 10.1007/s40264-018-0669-8


  • eng

Conference Location

  • New Zealand